• Active, not recruiting

NCT03151811: Phase 3- Melphalan Flufenamide (Melflufen)-Dex or Pom-dex for RRMM ref. to Len. (OCEAN)

Updated: Jun 15

OCEAN

NCT03151811: Phase 3: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

ocean study Melflufen

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients will receive either melflufen+dex or pomalidomide+dex.


Sponsor

Oncopeptides AB


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03151811

Official Title: A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide

First Posted : May 12, 2017


Click here for details on ClinicalTrials.gov

 

Melphalan Flufenamide (Melflufen) : National Cancer Institute

Melphalan Flufenamide (Melflufen) : MedlinePlus Drug Information

Pepaxto

 

Drug: Melflufen

Drug: Pomalidomide

Drug: Dexamethasone

 

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Lancet Haematol; 2022 Feb

Click here for details

 

Locations

United States, Arizona

United States, California

United States, Florida

United States, Idaho

United States, Kentucky

United States, Massachusetts

United States, Mississippi

United States, North Carolina

United States, Pennsylvania

United States, Texas

Europe

United Kingdom

Austria

Belgium

Czechia

Denmark

Estonia

France

Greece

Hungary

Italy

Lithuania

Netherlands

Norway

Poland

Romania

Spain

Asia

Israel

Korea, Republic of

Russian Federation

Taiwan




Posts Archive